NYSE · Medical Instruments & Supplies · USD
ResMed Inc. (RMD) Stock Analysis
ResMed Inc. (RMD) is a Medical Instruments & Supplies stock listed on NYSE and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RMD Key Statistics
As of Sep 4, 2026Trading
- Open
- $225.91
- Previous Close
- $229.19
- Day's Range
- 225.12–228.49
- 52-Week Range
- 180.27–284.87
- Volume
- 843.80K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.77
Valuation
- Market Cap
- $32.94B
- P/E Ratio
- 21.87
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 17.28
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 1.33
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 5.83
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 10.44
Financials (FY)
- Revenue (FY)
- $5.15B+9.84%
- Net Income (FY)
- $1.40B+37.20%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 26.95%
- Shares Outstanding
- 144.25M
- 1-Year Return
- −15.72%
Dividend and dates
- Dividend
- $2.64+1.16%
- Ex-Dividend Date
- August 20, 2026
- Earnings Date
- October 29, 2026estimated
- Avg Volume
- 1.48M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
RMD Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −4.42% |
| 2025 | +6.26% |
| 2024 | +34.18% |
| 2023 | −16.55% |
| 2022 | −19.47% |
| 2021 | +23.41% |
| 2020 | +38.33% |
| 2019 | +37.85% |
| 2018 | +36.38% |
| 2017 | +39.06% |
| 2016 (partial year) | −11.41% |
As of September 4, 2026.
RMD Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $5.15B | $1.40B | 27.2% |
| 2024 | $4.69B | $1.02B | 21.8% |
| 2023 | $4.22B | $897.56M | 21.3% |
| 2022 | $3.58B | $779.44M | 21.8% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $5.15B | $3.05B | $1.69B | $1.40B | 27.2% |
| 2024 | $4.69B | $2.66B | $1.38B | $1.02B | 21.8% |
| 2023 | $4.22B | $2.36B | $1.15B | $897.56M | 21.3% |
| 2022 | $3.58B | $2.02B | $1.00B | $779.44M | 21.8% |
Annual figures as reported, in the company's reporting currency. As of June 30, 2025.
RMD Dividend History
Dividends per share, 2025 · 4 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026* | $1.86 | 3 | — |
| 2025 | $2.26 | 4 | +11.9% |
| 2024 | $2.02 | 4 | +9.8% |
| 2023 | $1.84 | 4 | +7.0% |
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026 (partial year) | $1.86 | 3 | — |
| 2025 | $2.26 | 4 | +11.9% |
| 2024 | $2.02 | 4 | +9.8% |
| 2023 | $1.84 | 4 | +7.0% |
| 2022 | $1.72 | 4 | +6.2% |
| 2021 | $1.62 | 4 | +3.8% |
| 2020 | $1.56 | 4 | +2.6% |
| 2019 | $1.52 | 4 | +5.6% |
| 2018 | $1.44 | 4 | +5.9% |
| 2017 | $1.36 | 4 | +312.1% |
| 2016 | $0.33 | 1 | — |
Most recent payment: $0.62 per share, ex-dividend August 20, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
RMD Valuation vs Medical Instruments & Supplies Median
Median of 55 stocks| Metric | RMD | Medical Instruments & Supplies median | vs median |
|---|---|---|---|
| P/E | 21.87 | 35.61 | 39% below |
| P/S ratio | 5.83 | 3.17 | 84% above |
| Profit margin | 26.95% | 0.85% | 26.1 pts above |
Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts
ChartMillResMed Announces $450M Accelerated Share Repurchase Agreement With Citibank
BenzingaKeybanc Maintains Overweight on ResMed, Raises Price Target to $267
BenzingaResmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
YahooResMed Stock: Analyst Estimates & Ratings
Yahoo23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
Yahoo
All 20 articles ↓Show fewer ↑
Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation
FintelRothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
BenzingaResmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
YahooResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles
YahooThe 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
YahooResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook
YahooIs Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?
YahooResmed’s stock falls by 7% on soft FY27 outlook
YahooRMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts
YahooResMed Q4 Earnings Call Highlights
YahooRBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244
BenzingaRMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
YahooPiper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225
BenzingaResMed Shares Fall After Revenue Miss and Conservative 2027 Outlook
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Medical Instruments & Supplies Stocks
Intuitive Surgical, Inc.
$131.38B
BDXBecton, Dickinson and Company
$50.32B
MDLNMedline Inc.
$49.23B
ALCAlcon Inc.
$34.08B
WSTWest Pharmaceutical Services, Inc.
$23.93B
HOLXHologic, Inc.
$16.97B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B












